NASDAQ:TORC resTORbio (TORC) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free TORC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.49▼$1.7150-Day Range$2.28▼$14.7752-Week Range$0.86▼$10.50Volume3.10 million shsAverage Volume1.15 million shsMarket Capitalization$61.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get resTORbio alerts: Email Address Ad Birch GoldThe Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold now About resTORbio Stock (NASDAQ:TORC)Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.Read More Ad Birch GoldThe Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold now TORC Stock News HeadlinesJanuary 30, 2024 | investing.comAdicet Bio Inc (ACET)February 24, 2023 | finance.yahoo.comMichelle Chaka Joins Torc as Senior Vice President, Safety and RegulatoryMay 7, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Shocks Millions With US Dollar LunacyDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.January 10, 2023 | finance.yahoo.comTinOne Resources Inc. (TORC.V)September 19, 2022 | forbes.comCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - ForbesSeptember 12, 2022 | bizjournals.comFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business JournalsJuly 8, 2022 | streetinsider.comForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comJune 21, 2022 | gurufocus.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comMay 7, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Shocks Millions With US Dollar LunacyDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 1, 2022 | streetinsider.comTerns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comJune 1, 2022 | streetinsider.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comJune 1, 2022 | globenewswire.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GlobeNewswireApril 27, 2022 | streetinsider.comPureTech Announces Annual Results for Year Ended December 31, 2021 - StreetInsider.comApril 26, 2022 | businesswire.comPureTech Announces Annual Results for Year Ended December 31, 2021 - Business WireMarch 21, 2022 | businesswire.com$3.68 Billion Worldwide Cellular Immunotherapy Industry to 2031 - Identify Growth Segments for Investment - ResearchAndMarkets.com - Business WireMarch 15, 2022 | marketscreener.comADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.comFebruary 8, 2022 | seekingalpha.comAdicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate - Seeking AlphaJanuary 3, 2022 | forbes.comCan The Pharmaceutical Companies Use Basic Aging Biology To Develop Drugs For Age-Related Diseases? - ForbesDecember 9, 2021 | bizjournals.comAdicet soars on early clinical data for cancer cell therapy - San Francisco Business Times - San Francisco Business TimesNovember 11, 2021 | marketscreener.comADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.comOctober 30, 2021 | marketscreener.comADICET BIO, INC. : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.comOctober 20, 2021 | nasdaq.comNasdaq’s ConnectIR Surpasses 10,000 Bookings as Activity Surges Amid Pandemic - NasdaqAugust 12, 2021 | prnewswire.comGlobal Cellular Immunotherapy Market research Report 2021: Companies are Focusing on Developing Off-the-Shelf Allogeneic Therapies for New and Improved Cancer Treatment - PRNewswireAugust 3, 2021 | streetinsider.comOyster Point Pharma Announces New Chairperson Appointment to Board of Directors - StreetInsider.comAugust 3, 2021 | streetinsider.comOyster Point Pharma Inc. (OYST) Appoints Donald Santel to its Board - StreetInsider.comAugust 2, 2021 | finance.yahoo.comOyster Point Pharma Announces New Chairperson Appointment to Board of Directors - Yahoo FinanceSee More Headlines Receive TORC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for resTORbio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2020Today5/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TORC CUSIPN/A CIK1720580 Webwww.restorbio.com Phone(857) 315-5521FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,740,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-78.12% Return on Assets-71.63% Debt Debt-to-Equity RatioN/A Current Ratio20.69 Quick Ratio20.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book0.75Miscellaneous Outstanding Shares36,454,000Free FloatN/AMarket Cap$61.61 million OptionableNot Optionable Beta2.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesChen SchorPresident, CEO, Secretary & DirectorStewart AbbotSVP, Chief Operating & Scientific OfficerNick HarveyChief Financial OfficerFrancesco GalimiChief Medical Officer & Senior Vice PresidentDonald HealeyChief Technology OfficerKey CompetitorsLantern PharmaNASDAQ:LTRNBioLineRxNASDAQ:BLRXCleneNASDAQ:CLNNEagle PharmaceuticalsNASDAQ:EGRXHCW BiologicsNASDAQ:HCWBView All Competitors TORC Stock Analysis - Frequently Asked Questions How were resTORbio's earnings last quarter? resTORbio, Inc. (NASDAQ:TORC) issued its quarterly earnings results on Thursday, July, 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. What other stocks do shareholders of resTORbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include SCYNEXIS (SCYX), Novavax (NVAX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX) and CymaBay Therapeutics (CBAY). When did resTORbio IPO? resTORbio (TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:TORC) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldAI “wealth window” is closing June 25thParadigm PressCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
